Article
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Cytotherapy - 1 Apr 2020
Araujo B de Lima Vinicius, Borch Annie, Hansen Morten, Draghi Arianna, Spanggaard Iben, Rohrberg Kristoffer, Reker Hadrup Sine, Lassen Ulrik, Svane Inge Marie
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapeutic landscape and our perception of interactions between the immune system and tumor cells. Despite remarkable progress, disease relapse and primary resistance are not uncommon. Understanding the biological processes that tumor-infiltrating lymphocytes (TILs) undergo during ICI, how this affects the tumor microenvironment (TME)...
Topics
- Adult
- Aged
- B7-H1 Antigen
- Biopsy
- CD8-Positive T-Lymphocytes
- Female
- Follow-Up Studies
- Humans
- Immunologic Factors
- Immunotherapy
- Lymphocytes, Tumor-Infiltrating
